Evidence map›Paper›PMID 33238770›Full record

ArticleIntegrative cancer therapies

Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor.

Feiyu Shan, Leitao Sun, Leyin Zhang, Kaibo Guo, Qingying Yan, Guan Feng, Ying Zhu, Minhe Shen, Shanming Ruan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Feiyu ShanThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Leitao SunThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID 0000-0002-1441-3899
Leyin ZhangThe First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Kaibo GuoThe First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID 0000-0002-6348-9785
Qingying YanHangzhou Third Hospital, Hangzhou, Zhejiang, China.
Guan FengThe First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Ying ZhuThe First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Minhe ShenThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Shanming RuanThe First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.ORCID 0000-0003-1061-5255
Zhejiang Chinese Medical University · CNThird People's Hospital of Hangzhou · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundJiedu Sangen Decoction (JSD), a traditional Chinese medicine formula, has been widely applied in the treatment of gastrointestinal cancer, especially in colorectal cancer. Our study mainly aimed to assess the combined efficacy of Jiedu Sangen aqueous extract (JSAE) and a PD-L1 inhibitor (PI) in colon cancer cells migration and invasion, along with epithelial-mesenchymal transition, and then provide deep insights into the potential mechanism.

methodsWe explored the inhibitory effects on invasion and metastasis and the reverse effect on EMT process in CT-26 colon cancer cell via Transwell migration assay, Matrigel invasion assay and confocal laser scanning microscopy. Furthermore, regulation in expression of EMT-related proteins and molecular biomarkers and underlying signal pathway proteins were detected through Western blotting and IHC.

resultsThe combination of JSD and PD-L1 inhibitor could inhibit migration, invasive ability and EMT of CT-26 cells in a concentration-dependent manner. Meanwhile, JSD combined with PD-L1 inhibitor could also remarkably reverse EMT and metastasis in vivo. In addition, the protein expression of N-cadherin, Slug, Snail, Vimentin was down-regulated along with E-cadherin s up-regulation with the combination of JSD and PD-L1 inhibitor, while that of PI3K/AKT was notably down-regulated.

conclusionsThese findings indicated that JSAE and a PD-L1 inhibitor could drastically inhibit the migration and invasion of colorectal cancer by reversing EMT through the PI3K/AKT signaling pathway.

Indexed as

Colonic NeoplasmsEpithelial-Mesenchymal TransitionCell Line, TumorCell MovementHumansImmune Checkpoint InhibitorsMedicine, Chinese TraditionalNeoplasm InvasivenessPhosphatidylinositol 3-KinasesSnail Family Transcription FactorsImmune Checkpoint InhibitorsPhosphatidylinositol 3-KinasesSnail Family Transcription Factorscolorectal cancerepithelial-mesenchymal transitionJiedu Sangen decoctionmetastasisPI3K/AKT

Identifiers

PMID33238770
PMCPMC7705286
OpenAlexW3107482729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.